


CJC-1295 (with DAC)

2mg/ml

Alley

1. Description

CJC-1295 is a long acting GHRH analog peptide. Growth-hormone-releasing hormone (GHRH), is also known as growth-hormone-releasing factor (GRF or GHRF). The tetrahedral modifications of CJC 1295 with Drug Affinity Complex (DAC) lengthens the lifespan for releasing growth hormone (GH).



Drug Affinity Complex DAC-GRF (CJC-1295)

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight: 3368.7

CAS No.: 863288-34-0

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-Lys (Maleimidopropionyl)-NH₂ (Drug Affinity Complex)

CJC-1295(with DAC) is a sterile, non-pyrogenic, white lyophilized powder intended for subcutaneous or intramuscular injection, after reconstitution with sterile Water for Injection (0,3% m-Cresol).

2. Mechanism of action

CJC-1295 is in the class of growth hormone releasing hormone (GHRH) mimetics. CJC-1295 is a modified version of the first 29 amino acids of GHRH, together with addition of a "Drug Affinity Complex" or DAC. The combination of modifications provides a half-life of about 1 week, and steady blood levels after injection.

The DAC technology in the CJC-1295 enables the compound to bind itself covalently with any circulating albumin, after it has been administered through a subcutaneous injection. However, the reason why the half-life could be extended from a few minutes to several days is more profound. The reactive group in the CJC-1295 binds to a peptide through bio-conjugation. The peptide then finds a nucleophilic unit within the blood and reacts with it in order to create a firmer bond.

The principal use of CJC-1295 is to provide increased GH levels, which also results in increased IGF-1 levels. An increase in these levels can aid fat loss and in some instances can aid muscle gain as well. Generally, a product in the GHRH category, including CJC-1295, is chosen as an alternate to using GH, and only rarely is combined with GH.

In the healthy human body, large amounts of growth hormone are stored in the pituitary. As CJC-1295 is a GHRH, or Growth Hormone Releasing Hormone, acts like

one. The cells within the pituitary release growth hormone in response to signaling by GHRH. Then the peptide Ghrelin is (of which GHRPs – Growth Hormone Releasing Peptides – are mimetics), inhibited from releasing these stores by Somatostatin. GHRH and Ghrelin act on different populations of somatotropes (GH releasing cells). GHRP and Ghrelin increase the number of somatotropes releasing GH but not the amount released by each cell.

GHRH affects both the number of secreting cells and – more so – the amount they are actually able to secrete. GHRH and Ghrelin are released in specific patterns that vary depending on what the person involved is doing, or has been doing post-exercise. Now CJC-1295 DAC has been proven to stimulate slow wave sleep, and this is the period of sleep when most of your body's repairing work takes place on muscles and tissues.


3. Adverse reactions

CJC-1295 side effects are related to its stimulation of the pituitary gland. First, a surge of growth hormone (GH) will occur, sometimes causing vasodilation which is felt as a head rush or euphoria that lasts 30 minutes to 2 hours post injection.


Mild irritation such as itching, redness, and pain is frequently noticed at the injection site and is not severe in most cases. At the cellular level, CJC-1295 raises HGH, and research shows subjects have increased fat metabolism, increased muscular mass and strength, and improved skin tone and muscular definition. Diet and exercise in conjunction with CJC-1295 will enhance effects.

4. Instructions for reconstitution


Powder must be dissolved only with the solvent provided.



- 1a. Apply the needle to the syringe
1b. Remove the plastic cover from the vial



2. Break the top of the ampoule containing the solvent. Remove the plastic cover of the needle. Make sure the needle is well applied to the syringe. Slowly absorb all the solvent.



3. Inject all the solvent to the vial. This will create a 2mg/ml solution. To prevent foaming, the solvent should be injected into the vial by aiming the stream of liquid against the glass wall.



4. Following reconstitution, the vial should be swirled with a GENTLE rotary motion until the contents are completely dissolved. DO NOT SHAKE. The resulting solution should be clear and colorless, without particulate matter.

After reconstitution, the vial contains 1 ml liquid and 2mg CJC-1295(with DAC). That means 2000mcg/ml. For example one injection with 1000mcg CJC-1295 needs 0,5ml (or 50 units on Insulin Syringe).

5. Dosage

The main advantage of the CJC-1295(with DAC) is its 7-8 days half-life. The result is that the user can make only two injections per week, with a dosage of 1-2mg per injection. Combined with the every-day use of a GHRP injection, bring the best results.

6. Storage

- This product can be used not more than 3 years from the production date (see box)
- After reconstitution, may be stored for a maximum of 14 days in a refrigerator at 2°C - 8°C.
- Store vials in an upright position.
- Store in a refrigerator (2°C - 8°C). Keep in the outer carton in order to protect from light.
- For one month can be stored at room temperature.

THIS PRODUCT IS INTENDED FOR RESEARCH PURPOSES ONLY